衰老和癌症具有共同的细胞特征，包括细胞衰老、基因组不稳定以及异常细胞死亡和增殖，突出了治疗干预的潜在领域。靶向蛋白质降解技术的最新进展，特别是蛋白水解靶向嵌合体（PROTAC），为解决这些共享途径提供了一种有前途的方法。 PROTAC 利用泛素蛋白酶体系统特异性降解与癌症和衰老相关的致病蛋白，从而为关键致癌驱动因素和衰老相关细胞功能障碍提供潜在的解决方案。本摘要总结了 PROTAC 在靶向与癌症进展和衰老相关的关键蛋白质方面的最新进展，并探讨了整合这些技术以实现更有效的癌症治疗的未来前景。版权所有 © 2024 Elsevier Ltd。保留所有权利。

Aging and cancer share common cellular hallmarks, including cellular senescence, genomic instability, and abnormal cell death and proliferation, highlighting potential areas for therapeutic interventions. Recent advancements in targeted protein degradation technologies, notably Proteolysis-Targeting Chimeras (PROTACs), offer a promising approach to address these shared pathways. PROTACs leverage the ubiquitin-proteasome system to specifically degrade pathogenic proteins involved in cancer and aging, thus offering potential solutions to key oncogenic drivers and aging-related cellular dysfunction. This abstract summarizes the recent progress of PROTACs in targeting critical proteins implicated in both cancer progression and aging, and explores future perspectives in integrating these technologies for more effective cancer treatments.Copyright © 2024 Elsevier Ltd. All rights reserved.